statistiche ricercatore

Continente	#
NA - Nord America	546
EU - Europa	485
AS - Asia	399
SA - Sud America	52
AF - Africa	22
Continente sconosciuto - Info sul continente non disponibili	22
OC - Oceania	6
Totale	1.532

Nazione	#
US - Stati Uniti d'America	514
IT - Italia	225
SG - Singapore	113
VN - Vietnam	82
CN - Cina	64
IE - Irlanda	59
BD - Bangladesh	48
NL - Olanda	46
BR - Brasile	41
HK - Hong Kong	37
FR - Francia	29
DE - Germania	27
CA - Canada	18
GB - Regno Unito	16
CH - Svizzera	15
TW - Taiwan	15
RU - Federazione Russa	11
SE - Svezia	11
ZA - Sudafrica	11
FI - Finlandia	10
AT - Austria	9
BE - Belgio	7
IN - India	7
KR - Corea	7
IQ - Iraq	6
MX - Messico	6
PL - Polonia	5
AU - Australia	4
CO - Colombia	4
HU - Ungheria	4
CI - Costa d'Avorio	3
DZ - Algeria	3
ES - Italia	3
TH - Thailandia	3
TR - Turchia	3
CR - Costa Rica	2
CZ - Repubblica Ceca	2
EC - Ecuador	2
HN - Honduras	2
ID - Indonesia	2
IR - Iran	2
NI - Nicaragua	2
NZ - Nuova Zelanda	2
PE - Perù	2
SA - Arabia Saudita	2
SC - Seychelles	2
AR - Argentina	1
BO - Bolivia	1
CW - ???statistics.table.value.countryCode.CW???	1
EE - Estonia	1
EG - Egitto	1
HR - Croazia	1
IL - Israele	1
JM - Giamaica	1
JP - Giappone	1
KZ - Kazakistan	1
LB - Libano	1
MR - Mauritania	1
MY - Malesia	1
NO - Norvegia	1
PK - Pakistan	1
PT - Portogallo	1
QA - Qatar	1
SI - Slovenia	1
TN - Tunisia	1
TT - Trinidad e Tobago	1
UA - Ucraina	1
UZ - Uzbekistan	1
VE - Venezuela	1
Totale	1.511

Nome	#
Development of inhalation powders containing lactic acid bacteria with antimicrobial activity against Pseudomonas aeruginosa	247
An Enhanced Dissolving Cyclosporin-A Inhalable Powder Efficiently Reduces SARS-CoV-2 Infection In Vitro	245
The Impact of Possible Misuses Conditions on in Vitro Performance of NEXThaler in Comparison with Ellipta Inhaler	218
A dry powder formulation for peripheral lung delivery and absorption of an anti-SARS-CoV-2 ACE2 decoy polypeptide	172
LACTOBACILLI INHALATION POWDER FOR THE REDUCTION OF LUNG INFLAMMATION IN non-CF BRONCHIECTASIS DISEASE	153
The role of airways microbiota on local and systemic diseases: a rationale for probiotics delivery to the respiratory tract	152
Metered dose inhalers in the transition to low GWP propellants: what we know and what is missing to make it happen	117
PHARMACOKINETIC PROFILE INVESTIGATION OF PULMONARY SEMAGLUTIDE ENGINEERED POWDER	74
Drug delivery platforms for the inhalation of biologics	70
CaP-Coated Cyclosporine A Liposomes Formulated as an Inhalable Dry Powder for Lung Inflammatory Diseases	45
Lpb. plantarum inhalation powders for the reduction of lung inflammation and S. aureus growth control in non-CF bronchiectasis	27
Therapeutic potential of a long-acting form of rhDNase I for the treatment of cystic fibrosis	12
Totale	1.532

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2022/2023	40	0	0	0	0	0	0	9	6	10	8	4	3
2023/2024	171	4	2	2	6	12	23	52	11	3	5	27	24
2024/2025	299	11	13	15	30	16	20	49	21	32	23	24	45
2025/2026	634	42	37	63	53	47	24	103	21	90	57	58	39
2026/2027	388	50	91	104	143	0	0	0	0	0	0	0	0
Totale													1.532